Probiotic BC99 shows promise in fighting exercise fatigue
NCT ID NCT07325422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a probiotic called Weizmannia coagulans BC99 could help relieve exercise-induced fatigue in healthy college students. 72 participants took either the probiotic or a placebo daily for 12 weeks. The main goal was to measure changes in blood amino acid levels, which are linked to fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
72 people
The number who actually took part.
- Started
-
Nov 2023
- Finished
-
Mar 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Healthy adults aged 19-35 years, with no restriction on sex; 2. Physically active individuals with regular daily exercise training intensity and duration; 3. No history of allergy to protein products; 4. Body weight ≥50 kg for male subjects and ≥45 kg for female subjects; body mass index (BMI), calculated as weight (kg) divided by height squared (m²), within the range of 19.0-24.0 kg/m²; 5. No history of cardiovascular or cerebrovascular diseases, hypertension, diabetes, hepatic or renal dysfunction, or other underlying diseases or metabolic disorders; 6. Willingness to comply with the study protocol and study restrictions, and voluntary provision of written informed consent to participate in the study. Exclusion Criteria: 1. History of allergic constitution or immunodeficiency; 2. Blood donation or significant blood loss (≥200 mL) within 3 months prior to administration of the investigational product; 3. Presence of severe diseases of major organs, including the cardiovascular system, lungs, liver, or kidneys, as well as diabetes mellitus, severe thyroid disorders, metabolic diseases, malignant tumors, or severe immune system diseases; 4. Use of medications affecting the intestinal microbiota (including antibiotics, microecological preparations, intestinal mucosal protectants, traditional Chinese medicines, etc.) for more than one consecutive week within 1 month prior to screening; 5. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for College student are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wu Ying
Luoyang, Henan, 471000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.